PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 15, 2026Toxins0 citationsOpen Access

Patient Perceptions of a Preventive Effect of Long-Term Botulinum Neurotoxin Therapy in Cervical Dystonia

HHHarald HefterSSSara Samadzadeh

Key Points

  • This research aims to evaluate how patients with cervical dystonia perceive the effects of long-term botulinum neurotoxin therapy on their disease severity over time.
  • Screened 50 patients with idiopathic cervical dystonia receiving long-term botulinum neurotoxin therapy.
  • Included 43 patients in the analysis and assessed current disease severity as a percentage of its onset.
  • Patients estimated expected disease severity after 10 years if therapy was discontinued and drew graphs illustrating severity progression.
  • Compared expected severity with a previous assessment of patients who did not receive any therapy.
  • Patients estimated higher future disease severity if therapy is stopped compared to current severity (p < 0.001).
  • Expected severity after stopping therapy was lower than the hypothetical severity if no therapy had ever been administered (p < 0.001).
  • Patients believe long-term therapy prevents worsening of disease severity but do not expect to experience the worst possible severity.

Abstract

Patients with cervical dystonia (CD) often believe that disease severity would have progressed beyond the pre-treatment level if botulinum neurotoxin (BoNT) therapy had not been initiated. The aim of the present study was to assess the perceptions of long-term BoNT-treated patients with CD regarding the expected course of disease severity over the next 10 years under the hypothetical assumption that BoNT therapy is discontinued. Fifty patients with idiopathic CD receiving long-term BoNT therapy were screened, and 43 patients were included. Disease severity at the day of recruitment was assessed as a percentage of CD severity at the onset of BoNT therapy (PAS-%). Patients also generated, in a standardized manner, a graph illustrating the development of CD severity since initiation of BoNT therapy. Subsequently, patients estimated the expected severity of CD after 10 years, expressed as a percentage of severity at BoNT therapy onset (PAS-STD), under the hypothetical assumption that BoNT therapy was discontinued at the time of recruitment. They additionally drew a graph depicting the anticipated progression of CD severity over the subsequent 10 years under this assumption. Furthermore, 33 of these 43 patients had previously assessed the expected development of CD severity under the assumption that no BoNT therapy had ever been performed (PAS-NO%) in an earlier study. Mean PAS-STD was significantly higher than mean PAS-% (p < 0.001). Comparison of mean PAS-STD with mean PAS-NO% in the 33 patients who participated in both studies demonstrated that mean PAS-STD was significantly lower than mean PAS-NO% (p < 0.001). Long-term BoNT-treated patients with CD believe that disease severity would worsen again if BoNT therapy were discontinued. However, they do not expect CD severity to deteriorate to the level that they believe would have been reached if no BoNT therapy had been administered. We interpret this finding as suggesting that patients perceive a preventive effect of long-term BoNT therapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hefter et al. (2026) studied this question.

synapsesocial.com/papers/69df2cf7e4eeef8a2a6b20fbhttps://doi.org/10.3390/toxins18040184
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin2016 · 31 citations
  2. 2Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study2018 · 24 citations
  3. 3The Cervical Dystonia Impact Profile (CDIP-58): Can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?2008 · 28 citations
  4. 4Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement2015 · 80 citations
  5. 5Epidemiology of focal and generalized dystonia in Rochester, Minnesota1988 · 482 citations